We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Revvity (RVTY - Free Report) . Shares have lost about 8.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Revvity due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Revvity reported third-quarter 2024 adjusted earnings per share of $1.28, which beat the Zacks Consensus Estimate of $1.13 by 13.3%. The bottom line improved 8.5% from the year-ago quarter’s level.
GAAP earnings per share from continuing operations was 76 cents compared with 26 cents in the prior-year period. However, GAAP earnings per share in the reported quarter was 77 cents, which includes a loss of 1 cent per share from discontinued operations.
Revenue Details
The company reported revenues of $684 million, up 2% year over year as well as organically. The top line surpassed the Zacks Consensus Estimate by 9.4%.
Segmental Details
Life Sciences
Revenues from this segment totaled $300.9 million, indicating a decrease of 2.3% from the year-ago quarter’s level. Organically, the segment witnessed a decline of 3% year over year.
Adjusted operating income amounted to $102.9 million, down 9.8% from the prior-year quarter.
Diagnostics
This segment’s revenues totaled $383.3 million, up 5.6% on a year-over-year basis. Organically, the top line increased 5% year over year.
Adjusted operating income amounted to $101.4 million, up 24.1% from the year-ago quarter’s figure.
Margin Analysis
Selling, general and administrative expenses totaled $237.5 million, down 5.1% year over year. Research and development expenses amounted to $49.1 million, down 7.4% from the year-ago quarter’s reported number.
Adjusted operating income improved 4.8% to $193.5 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 28.3%, expanding 80 basis points.
Financial Update
The company exited the third quarter of 2024 with cash and cash equivalents of $1.23 billion compared with $1.95 billion in the prior-quarter end.
Net cash provided by operating activities, including discontinued operations, totaled $147.9 million compared with net cash used in operating activities of $33.5 million in the year-ago quarter.
2024 Guidance
Revvity raised its earnings and updated its revenue guidance for 2024.
For 2024, the company now expects its adjusted earnings per share in the range of $4.83-$4.87 compared with the prior guidance of $4.70-$4.80. Revenues are now anticipated to be in the band of $2.75-$2.77 billion.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month.
VGM Scores
Currently, Revvity has a subpar Growth Score of D, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Revvity has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Revvity is part of the Zacks Medical Services industry. Over the past month, Teladoc (TDOC - Free Report) , a stock from the same industry, has gained 19.7%. The company reported its results for the quarter ended September 2024 more than a month ago.
Teladoc reported revenues of $640.51 million in the last reported quarter, representing a year-over-year change of -3%. EPS of -$0.19 for the same period compares with -$0.35 a year ago.
For the current quarter, Teladoc is expected to post a loss of $0.20 per share, indicating a change of -17.7% from the year-ago quarter. The Zacks Consensus Estimate has changed -8.9% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Teladoc. Also, the stock has a VGM Score of A.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report?
It has been about a month since the last earnings report for Revvity (RVTY - Free Report) . Shares have lost about 8.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Revvity due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised
Revvity reported third-quarter 2024 adjusted earnings per share of $1.28, which beat the Zacks Consensus Estimate of $1.13 by 13.3%. The bottom line improved 8.5% from the year-ago quarter’s level.
GAAP earnings per share from continuing operations was 76 cents compared with 26 cents in the prior-year period. However, GAAP earnings per share in the reported quarter was 77 cents, which includes a loss of 1 cent per share from discontinued operations.
Revenue Details
The company reported revenues of $684 million, up 2% year over year as well as organically. The top line surpassed the Zacks Consensus Estimate by 9.4%.
Segmental Details
Life Sciences
Revenues from this segment totaled $300.9 million, indicating a decrease of 2.3% from the year-ago quarter’s level. Organically, the segment witnessed a decline of 3% year over year.
Adjusted operating income amounted to $102.9 million, down 9.8% from the prior-year quarter.
Diagnostics
This segment’s revenues totaled $383.3 million, up 5.6% on a year-over-year basis. Organically, the top line increased 5% year over year.
Adjusted operating income amounted to $101.4 million, up 24.1% from the year-ago quarter’s figure.
Margin Analysis
Selling, general and administrative expenses totaled $237.5 million, down 5.1% year over year. Research and development expenses amounted to $49.1 million, down 7.4% from the year-ago quarter’s reported number.
Adjusted operating income improved 4.8% to $193.5 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 28.3%, expanding 80 basis points.
Financial Update
The company exited the third quarter of 2024 with cash and cash equivalents of $1.23 billion compared with $1.95 billion in the prior-quarter end.
Net cash provided by operating activities, including discontinued operations, totaled $147.9 million compared with net cash used in operating activities of $33.5 million in the year-ago quarter.
2024 Guidance
Revvity raised its earnings and updated its revenue guidance for 2024.
For 2024, the company now expects its adjusted earnings per share in the range of $4.83-$4.87 compared with the prior guidance of $4.70-$4.80. Revenues are now anticipated to be in the band of $2.75-$2.77 billion.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month.
VGM Scores
Currently, Revvity has a subpar Growth Score of D, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Revvity has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Revvity is part of the Zacks Medical Services industry. Over the past month, Teladoc (TDOC - Free Report) , a stock from the same industry, has gained 19.7%. The company reported its results for the quarter ended September 2024 more than a month ago.
Teladoc reported revenues of $640.51 million in the last reported quarter, representing a year-over-year change of -3%. EPS of -$0.19 for the same period compares with -$0.35 a year ago.
For the current quarter, Teladoc is expected to post a loss of $0.20 per share, indicating a change of -17.7% from the year-ago quarter. The Zacks Consensus Estimate has changed -8.9% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Teladoc. Also, the stock has a VGM Score of A.